Submit Manuscript  

Article Details


The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes

[ Vol. 13 , Issue. 3 ]

Author(s):

Piero Ruscitti*, Paola Cipriani, Vasiliky Liakouli, Francesco Carubbi, Onorina Berardicurti, Paola Di Benedetto, Francesco Ciccia, Giuliana Guggino, Saverio Alvaro, Giovanni Triolo and Roberto Giacomelli   Pages 210 - 214 ( 5 )

Abstract:


Background: Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients.

Objective: We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process.

Method: After literature search, the available evidence has been selected and commented in the text.

Results: During RA, it is well known that different inflammatory cytokines, such as interleukin-1β (IL-1β), are pivotal pathogenic mediators and their role has been largely confirmed in clinical settings. Similarly, it has been shown that the excess of nutrients, secondary to over-nutrition, may activate the immune system, leading to an increased production of inflammatory cytokines, including IL-1β, suggesting new possible therapeutic targets.

Conclusion: Although further studies are needed to fully investigate the pathogenic interplay between inflammation and metabolic disorders, IL-1β has been implicated in both RA and T2D pathogenic mechanisms. Intriguingly, the potential role of anti-IL-1 drugs has been proposed in RA patients affected by T2D.

Keywords:

Anakinra, cardiovascular risk, diabetes, IL-1β, pathogenesis, rheumatoid arthritis, therapy.

Affiliation:

Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila, Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila, Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila, Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila, Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila, Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila, Rheumatology Section, Department of Internal Medicine, University of Palermo, Palermo, Rheumatology Section, Department of Internal Medicine, University of Palermo, Palermo, Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila, Rheumatology Section, Department of Internal Medicine, University of Palermo, Palermo, Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila

Graphical Abstract:



Read Full-Text article